ANI PHARMACEUTICALS INC (ANIP)
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms
estradiol gel
Hot Flashes
NCT00391417Enrollment431StartSep 2003Primary Completion-CompletionApr 2005 - Phase 3Completed
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
testosterone gel, placebo gel
Hypoactive Sexual Desire Disorder
NCT00612742Enrollment3,656StartJan 2008Primary CompletionOct 2012CompletionDec 2012 - Phase 3Completed
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
testosterone gel, placebo gel
Hypoactive Sexual Desire Disorder
NCT00613002Enrollment597StartDec 2006Primary CompletionSep 2011CompletionSep 2011 - Phase 3Completed
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
testosterone gel, placebo gel
Hypoactive Sexual Desire Disorder
NCT00657501Enrollment575StartMar 2008Primary CompletionSep 2011CompletionSep 2011 - Phase 3Completed
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
transdermal testosterone gel 1%, placebo gel
Hypoactive Sexual Desire Disorder
NCT01235754Enrollment626StartOct 2010Primary CompletionDec 2011CompletionJan 2012
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | estradiol gel | NCT00391417 |
| Phase 3 | Completed | testosterone gel, placebo gel | NCT00612742 |
| Phase 3 | Completed | testosterone gel, placebo gel | NCT00613002 |
| Phase 3 | Completed | testosterone gel, placebo gel | NCT00657501 |
| Phase 3 | Completed | transdermal testosterone gel 1%, placebo gel | NCT01235754 |